Pharmacological properties of a combination of the antirheumatic drug Benetazone (trimetazone) and the analgesic drug dextropropoxyphene
Grimová, J.; Nĕmecek, O.; Rádek, O.; Volková, Z.
Ceskoslovenska Farmacie 23(1): 28-33
1974
ISSN/ISBN: 0009-0530 PMID: 4458971 Document Number: 80421
Document emailed within 1 workday
Related Documents
Rafanell, J.G.; Bellés, L.; Sánchez, M.S.; Forn, J. 1980: Pharmacological study of 2-phosphonoxybenzoic acid (fosfosal), a new analgesic drug Arzneimittel-Forschung 30(7): 1091-1098Arneson, H.T.; Colton, R.S. 1987: Drug-drug interaction with the use of antirheumatic drugs Minnesota Medicine 70(10): 589; 592
Lampa, E.; Romano, A.R.; Berrino, L.; Tortora, G.; Di Guglielmo, R.; Filippelli, A.; Gentile, B.; Marmo, E. 1985: Pharmacological properties of a new non-steroidal anti-inflammatory drug: flunoxaprofen Drugs under Experimental and Clinical Research 11(8): 501-509
Bellamy, N.; Anastassiades, T.P.; Buchanan, W.W.; Davis, P.; Lee, P.; McCain, G.A.; Wells, G.A.; Campbell, J. 1991: Rheumatoid arthritis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials of antirheumatic drugs Journal of Rheumatology 18(12): 1901-1907
Magnanini, R.; Mazzoni, G.; Musiani, M.; Orlandi, V.; D'Antonio, C. 1982: Clinical control of the therapeutic action of a decontracting, anti-rheumatic, analgesic drug combination for topical use, in comparison with oxyphenbutazone La Clinica Terapeutica 101(2): 151-165
2009: Dextropropoxyphene: withdrawal from the US market requested: harmful drug Prescrire International 18(102): 166-167
Emilien, G.; Maloteaux, J.M. 1998: Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities International Journal of Clinical Pharmacology and Therapeutics 36(4): 181-194
Lehmann, H.; Hirsch, U.; Bauer, E.; Bauer, M.; Greischel, A.; Schmid, J.; Schneider, P. 1996: Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys Arzneimittel-Forschung 46(9): 895-905
Urquhart, J. 1984: Pharmacological and therapeutic aspects of drug administration by rate-controlled drug delivery systems: steady-state pharmacology Bollettino Chimico Farmaceutico 123(4): 155-168
Breithaupt, H. 1994: Drug-induced liver damage caused by antirheumatic drugs--antirheumatic therapy in pre-existing liver damage Zeitschrift für Rheumatologie 53(4): 250-254
Duhault, J.; Boulanger, M.; Tisserand, F.; Bergi, L. 1972: The pharmacology of S 1702, a new highly effective oral antibiabetic drug with unusual properties. 1. Pharmacological and hypoglycaemic activity, studies in different animal species Arzneimittel-Forschung 22(10): 1682-1685
Furue, H. 1986: Application and problems of combination drug therapy--drug interactions of antineoplastic agents and antibiotics Nihon Rinsho. Japanese Journal of Clinical Medicine 44(4): 942-946
Allen, T.M.; Everest, J.M. 1983: Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats Journal of Pharmacology and Experimental Therapeutics 226(2): 539-544
Nakamura, H.; Kadokawa, T.; Nakatsuji, K.; Nakamura, K. 1970: Pharmacological studies of a new anti-inflammatory drug, 1-phenylsulfonyl-5,5-diphenylhydantoin (PC-796) in experimental animals. I. Anti-inflammatory, analgesic and anti-pyretic activity Arzneimittel-Forschung 20(8): 1032-1046
Andersson, M.L.; Böttiger, Y.; Lindh, J.D.; Wettermark, B.; Eiermann, B. 2013: Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care European Journal of Clinical Pharmacology 69(3): 565-571
Goldsmith, C.H. 1991: Challenges in designing antirheumatic drug trials Journal of Rheumatology 18(11): 1643-1644
Buchanan, W.W.; Kean, W.F. 1987: Implications of antirheumatic drug therapy in elderly patients with osteoarthritis Journal of Rheumatology 14(Special Issue): 98-100
Zanasi, R.; Volonteri, G.; Castaldi, D. 1971: Clinical evaluation of the use in arthrosis of a drug with antirheumatic and anti-inflammatory action Minerva Medica 62(3): 174-178
Griem, P.; Takahashi, K.; Kalbacher, H.; Gleichmann, E. 1995: The antirheumatic drug disodium aurothiomalate inhibits CD4+ T cell recognition of peptides containing two or more cysteine residues Journal of Immunology 155(3): 1575-1587
Wolfe, F.; Rehman, Q.; Lane, N.E.; Kremer, J. 2001: Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment Journal of Rheumatology 28(7): 1704-1711